FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:681-690 March 10, 1994 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Insanity has afflicted humanity throughout history¹. At the turn of this century, identification of the syphilitic insanities set the stage for Kraepelin to recognize the distinctive symptom patterns of the manic-depressive psychoses and dementia praecox². In 1911, Bleuler noted that the early onset of dementia was not characteristic of Kraepelin's dementia praecox, and he coined the term "schizophrenia" to refer to the dissociation or disruption of thought processes and the split among thought, emotion, and behavior³. With recent diagnostic refinements, psychosis (that is, a break with reality usually manifested as hallucinations, delusions, or a disruption in thought . . . [Full Text of this Article]

Diagnosis

Course and Outcome

Epidemiology and Causes

Pathophysiology

Treatment

Pharmacotherapy

Psychosocial Treatment and Rehabilitation

Systems of Care

Source Information

From the University of Maryland School of Medicine, Maryland Psychiatric Research Center, P.O. Box 21247, Baltimore, MD 21228, where reprint requests should be addressed to Dr. Carpenter.

References

Related Letters:

Schizophrenia
Mosqueda R. A., Davidson J. E., Carpenter W. T., Buchanan R. W.
Extract | Full Text  
N Engl J Med 1994; 331:275-276, Jul 28, 1994. Correspondence

This article has been cited by other articles:

• HeiSer, P., Enning, F., Krieg, J.-C., Vedder, H. (2007). Effects of haloperidol, clozapine and olanzapine on the survival of human neuronal and immune cells in vitro. J Psychopharmacol 21: 851-856 [Abstract]  
• Hassan, M., Madhavan, S S., Kalsekar, I. D, Makela, E. H, Rajagopalan, K., Islam, S., Kavookjian, J., Miller, L.-A. (2007). Comparing Adherence to and Persistence with Antipsychotic Therapy Among Patients with Bipolar Disorder. The Annals of Pharmacotherapy 41: 1812-1818 [Abstract] [Full Text]  
• Tamminga, C. A., Davis, J. M. (2007). The Neuropharmacology of Psychosis. Schizophr Bull 33: 937-946 [Abstract] [Full Text]  
• Burton, S. (2006). Symptom domains of schizophrenia: the role of atypical antipsychotic agents.. J Psychopharmacol 20: 6-19 [Abstract]  
• Clinton, S. M., Ibrahim, H. M., Frey, K. A., Davis, K. L., Haroutunian, V., Meador-Woodruff, J. H. (2005). Dopaminergic Abnormalities in Select Thalamic Nuclei in Schizophrenia: Involvement of the Intracellular Signal Integrating Proteins Calcyon and Spinophilin. Am. J. Psychiatry 162: 1859-1871 [Abstract] [Full Text]  
• Gould, R. A., Mueser, K. T., Bolton, E., Mays, V., Goff, D. (2004). Cognitive Therapy for Psychosis in Schizophrenia: An Effect Size Analysis. Focus 2: 95-101 [Abstract] [Full Text]  
• Carpenter, W. T. Jr., Appelbaum, P. S., Levine, R. J. (2003). The Declaration of Helsinki and Clinical Trials: A Focus on Placebo-Controlled Trials in Schizophrenia. Am. J. Psychiatry 160: 356-362 [Abstract] [Full Text]  
• Strous, R. D., Maayan, R., Lapidus, R., Stryjer, R., Lustig, M., Kotler, M., Weizman, A. (2003). Dehydroepiandrosterone Augmentation in the Management of Negative, Depressive, and Anxiety Symptoms in Schizophrenia. Arch Gen Psychiatry 60: 133-141 [Abstract] [Full Text]  
• Lahti, A. C., Holcomb, H. H., Medoff, D. R., Weiler, M. A., Tamminga, C. A., Carpenter, W. T. Jr. (2001). Abnormal Patterns of Regional Cerebral Blood Flow in Schizophrenia With Primary Negative Symptoms During an Effortful Auditory Recognition Task. Am. J. Psychiatry 158: 1797-1808 [Abstract] [Full Text]  
• Baare, W. F.C., Hulshoff Pol, H. E., Boomsma, D. I., Posthuma, D., de Geus, E. J.C., Schnack, H. G., van Haren, N. E.M., van Oel, C. J., Kahn, R. S. (2001). Quantitative Genetic Modeling of Variation in Human Brain Morphology. Cereb Cortex 11: 816-824 [Abstract] [Full Text]  
• Baare, W. F. C., van Oel, C. J., Hulshoff Pol, H. E., Schnack, H. G., Durston, S., Sitskoorn, M. M., Kahn, R. S. (2001). Volumes of Brain Structures in Twins Discordant for Schizophrenia. Arch Gen Psychiatry 58: 33-40 [Abstract] [Full Text]  
• Nimgaonkar, V. L., Fujiwara, T. M., Dutta, M., Wood, J., Gentry, K., Maendel, S., Morgan, K., Eaton, J. (2000). Low Prevalence of Psychoses Among the Hutterites, an Isolated Religious Community. Am. J. Psychiatry 157: 1065-1070 [Abstract] [Full Text]  
• Carpenter, W. T. Jr, Gold, J. M., Lahti, A. C., Queern, C. A., Conley, R. R., Bartko, J. J., Kovnick, J., Appelbaum, P. S. (2000). Decisional Capacity for Informed Consent in Schizophrenia Research. Arch Gen Psychiatry 57: 533-538 [Abstract] [Full Text]  
• Fujian Song, (1997). Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. J Psychopharmacol 11: 65-71 [Abstract]  
• Spitzer, V. M. (1995). Biological Aspects of Schizophrenia. J Am Psychiatr Nurses Assoc 1: 204-207 [Abstract]  
• Mosqueda, R. A., Davidson, J. E., Carpenter, W. T., Buchanan, R. W. (1994). Schizophrenia. NEJM 331: 275-276 [Full Text]